Interpretation of perioperative immunotherapy for lung cancer in 2024 WCLC/ESMO
- VernacularTitle:2024年WCLC/ESMO肺癌围手术期免疫治疗进展解读
- Author:
Jiahe LI
1
;
Xiaopeng REN
2
;
Jiayu LU
3
;
Chenyuan ZHANG
3
;
Ruitao FAN
3
;
Xuxu ZHANG
1
;
Xinyao XU
4
;
Guizhen LI
4
;
Jipeng ZHANG
4
;
Wei LI
4
;
Qiang LU
4
Author Information
1. 1. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China 2. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi an, 710038, P. R. China
2. 1. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China
3. Basic Medical College, Air Force Medical University, Xi an, 710032, P. R. China
4. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi an, 710038, P. R. China
- Publication Type:Journal Article
- Keywords:
Lung cancer;
World Conference on Lung Cancer;
European Society for Medical Oncology;
perioperative treatment;
immunity
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(03):300-307
- CountryChina
- Language:Chinese
-
Abstract:
The 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Annual Meeting, two of the most prestigious events in oncology, have concluded sequentially. As the most authoritative annual gatherings in lung cancer and the entire oncology field, the WCLC and ESMO conferences brought together top oncology experts and scientists from around the world to share, discuss, and publish the latest cutting-edge advancements in oncology. In both conferences, lung cancer immunotherapy remained a hot topic of considerable interest. This article aims to summarize and discuss the important research progress on perioperative immunotherapy for non-small cell lung cancer reported at the two conferences.
